スポンサーリンク
Department Of Breast Surgery Cancer Institute Hospital | 論文
- Overrepresentation of the EBAG9 Gene at 8q23 Associated with Early-Stage Breast Cancers
- Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer
- Allelic Losses of Loci at 3p25.1,8p22,13q12,17p13.3,and 22q13 Correlate with Postoperative Recurrence in Breast Cancer
- Ocular Pharmacokinetic/Pharmacodynamic Modeling for Multiple Anti-glaucoma Drugs
- Influence of murine hepatitis induced by D-(+)-galactosamine hydrochloride and lipopolysaccharide on gene expression of polyethylenimine/plasmid DNA polyplex
- Ocular Pharmacokinetic/Pharmacodynamic Modeling for Timolol in Rabbits Using a Telemetry System
- Partial Hepatectomy Enhances Polyethylenimine-Mediated Plasmid DNA Delivery
- Antimicrobial Activity of Saturated Fatty Acids and Fatty Amines against Methicillin-Resistant Staphylococcus aureus
- Sensitive and Real-Time Method for Evaluating Corneal Barrier Considering Tear Flow
- Identification of a 1-Mb Common Region at 16q24.1-24.2 Deleted in Hepatocellular Carcinoma
- Allelic Loss at 1p34,13q12,17p13.3,and 17q21.1 Correlates With Poor Postoperative Prognosis in Breast Cancer
- Identification of a 1-cM Region of Common Deletion on 4q35 Associated With Progression of Hepatocellular Carcinoma
- Correlation of Allelic Loss with Poor Postoperative Survival in Breast Cancer
- PTEN/MMAC1 Mutations in Hepatocellular Carcinomas: Somatic Inactivation of Both Alleles in Tumors
- Frequent Allelic Loss at 6q26-27 in Breast Carcinomas of the Solid-tubular Histologic Type
- Detailed Deletion Mapping of Chromosome Arm 3p in Breast Cancers : A 2-cM Region on 3p 14.3-21.1 and a 5-cM Region on 3p 24.3-25.1 Commonly Deleted in Tumors
- Correlation of Allelic Losses and Clinicopathological Factors in Primary Breast Cancers
- Mapping of a Breast Cancer Tumor Suppressor Gene Locus to a 4-cM Interval on Chromosome 18q21
- Efficacy and Safety of Combined Trastuzumab and Paclitaxel Therapy as a Second-Line Treatment in Women with Metastatic Breast Cancer : A Single Institutional Experience
- High Prevalence of HER-2/neu and p53 Overexpression in Inflammatory Breast Cancer